The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

Vaccine

Volumn 29, Issue 42, 2011, Pages 7267-7275

  Coller, Beth Ann G ^a   Clements, David E ^a   Bett, Andrew J ^a   Sagar, Sangeetha L ^a   Ter Meulen, Jan H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dengue; Recombinant; Subunit; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; DENGUE VACCINE; ENVELOPE PROTEIN; LIVE VACCINE; MIFAMURTIDE; NEUTRALIZING ANTIBODY; RECOMBINANT SUBUNIT ENVELOPE BASED VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; BACULOVIRUS; CLONING; DENGUE; DENGUE VIRUS; DROSOPHILA; ESCHERICHIA COLI; EXPERIMENTAL MODEL; HUMAN; IMMUNITY; IMMUNOGENICITY; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; SINGLE DRUG DOSE; VACCINIA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DROSOPHILA; GENE EXPRESSION; HUMANS; MICE; PRIMATES; PROTEIN CONFORMATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 80052410152     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.021     Document Type: Article

References (66)

1. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8(12 Suppl.):S7-S16.
2. Whitehorn J., Farrar J. Dengue. Br Med Bull 2010, 95:161-173.
3. Tapia-Conyer R., Méndez-Galván J.F., Gallardo-Rincón H. The growing burden of dengue in Latin America. J Clin Virol 2009, 46(Suppl. 2):S3-S6.
4. Halstead S.B. Dengue. Lancet 2007, 370:1644-1652.
5. Srikiatkhachorn A., Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol 2010, 338:67-82.
6. Balsitis S.J., Williams K.L., Lachica R., Flores D., Kyle J.L., Mehlhop E., et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010, 6:e1000790.
7. Halstead S.B. Antibodies determine virulence in dengue. Ann NY Acad Sci 2009, 1171(Suppl. 1):E48-E56.
8. Mathew A., Rothman A.L. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev 2008, 225:300-313.
9. Noisakran S., Chokephaibulkit K., Songprakhon P., Onlamoon N., Hsiao H.-M., Villinger F., et al. A re-evaluation of the mechanisms leading to dengue hemorrhagic fever. Ann NY Acad Sci 2009, 1171:E24-E35.
10. Mongkolsapaya J., Dejnirattisai W., Xu X.-N., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003, 9:921-927.
11. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003, 69(6 Suppl.):24-31.
12. Blok J., McWilliam S.M., Butler H.C., Gibbs A.J., Weiller G., Herring B.L., et al. Comparison of a dengue-2 virus and its candidate vaccine derivative: sequence relationships with the flaviviruses and other viruses. Virology 1992, 187:573-590.
13. Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003, 69(6 Suppl.):48-60.
14. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006, 24:1238-1241.
15. Sun W., Cunningham D., Wasserman S.S., Perry J., Putnak J.R., Eckels K.H., et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccin 2009, 5:33-40.
16. Jaiswal S., Khanna N., Swaminathan S. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol 2003, 77:12907-12913.
17. Raviprakash K., Wang D., Ewing D., Holman D.H., Block K., Woraratanadharm J., et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008, 82:6927-6934.
18. Fonseca B.A.L., Pincus S., Shope R.E., Paoletti E., Mason P.W. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 1994, 12:279-285.
19. White L.J., Parsons M.M., Whitmore A.C., Williams B.M., de Silva A., Johnston R.E. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol 2007, 81:10329-10339.
20. De Paula S.O., Lima D.M., deOliveira Franca R.F., Gomes-Ruiz A.C., da Fonseca B.A. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge. Arch Virol 2008, 153:2215-2223.
21. Brandlera S., Ruffiea C., Najburga V., Frenkielb M.-P., Bedouelleb H., Desprèsb P., et al. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 2010, 28:6730-6739.
22. Kochel T., Wu S.J., Raviprakash K., Hobart P., Hoffman S., Porter K., et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997, 15:547-552.
23. Raviprakash K., Kochel T.J., Ewing D., Simmons M., Phillips I., Hayes C.G., et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000, 18:2426-2434.
24. Trent D.W. Antigenic characterization of flavivirus structural proteins separated by isoelectric focusing. J Virol 1977, 22:608-618.
25. Henchal E.A., Gentry M.K., McCown J.M., Brandt W.E. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 1982, 31:830-836.
26. Roehrig J.T., Bolin R.A., Kelly R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246:317-328.
27. Beltramello M., Williams K.L., Simmons C.P., Macagno A., Simonelli L., Quyen N.T.H., et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010, 8:271-283.
28. Durbin A.P., Whitehead S.S. Dengue vaccine candidates in development. Dengue virus, current topics in microbiology and immunology 2010, 129-143. A.L. Rothman (Ed.).
29. Yap Y.-K., Smith D.R. Strategies for the plant-based expression of dengue subunit vaccines. Biotechnol Appl Biochem 2010, 57:47-53.
30. Allison S.L., Stadler K., Mandl C.W., Kunz C., Heinz F.X. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Virol 1995, 69:5816-5820.
31. Feighny R., Burrous J., Putnak R. Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge. Am J Trop Med Hyg 1994, 50:322-328.
32. Mason P.W., Zugal M.U., Semproni A.R., Fournier M.J., Mason T.L. The antigenic structure of dengue type 1 virus envelope and NS1 proteins expressed in Escherichia coli. J Gen Virol 1990, 71:2107-2114.
33. Megret F., Hugnot J.P., Falconar A., Gentry M.K., Morens D.M., Murray J.M., et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 1992, 187:480-491.
34. Hermida L., Rodriguez R., Lazo L., Silva R., Zulueta A., Chinea G., et al. A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 2004, 115:41-49.
35. Simmons C.P., Farrar J. Changing patterns of dengue epidemiology and implications for clinical management and vaccines. PLoS Med 2009, 9:e1000129.
36. Srivastava A.K., Putnak J.R., Warren R.L., Hoke C.H. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 1995, 13:1251-1258.
37. Bielefeldt-Ohmann H., Beasley D.W., Fitzpatrick D.R., Aaskov J.G. Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system. J Gen Virol 1997, 78:2723-2733.
38. Delenda C., Staropoli I., Frenkiel M.P., Cabanie L., Deubel V. Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. J Gen Virol 1994, 75:1569-1578.
39. Deubel V., Bordier M., Megret F., Gentry M.K., Schlesinger J.J., Girard M. Processing, secretion, and immunoreactivity of carboxy terminally truncated dengue-2 virus envelope proteins expressed in insect cells by recombinant baculoviruses. Virology 1991, 180:442-447.
40. Kelly E.P., Greene J.J., King A.D., Innis B.L. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 2000, 18:2549-2559.
41. Putnak R., Feighny R., Burrous J., Cochran M., Hackett C., Smith G., et al. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am J Trop Med Hyg 1991, 45:159-167.
42. Men R.H., Bray M., Lai C.J. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. J Virol 1991, 65:1400-1407.
43. Sugrue R.J., Fu J., Howe J., Chan Y.C. Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. J Gen Virol 1997, 78:1861-1866.
44. Liu W., Jiang H., Zhou J., Yang X., Tang Y., Fang D., et al. Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties. Virus Genes 2010, 40:53-59.
45. Konishi E., Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 2002, 20:1058-1067.
46. Chang G.J.J., Hunt A.R., Holmes D.A., Springfield T., Chiueh T.S., Roehrig J.T., et al. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 2003, 306:170-180.
47. Kuwahara M., Konishi E. Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens. Clin Vac Immunol 2010, 17:1560-1566.
48. Ivy J, Nakano E, Clements D. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila malanogaster expression systems 2000; US Patent 6136561.
49. van der Straten A., Johansen H., Rosenberg M., Sweet R.W. Introduction and constitutive expression of gene products in cultured drosophila cells using hygromycin B selection. Methods Mol Cell Biol 1989, 1:1-8.
50. Culp J.S., Johansen H., Hellmig B., Beck J., Matthews T.J., Delers A., et al. Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells. Biotechnology 1991, 9:173-177.
51. Kirkpatrick R.B., Shatzman A. Drosophila S2 system for heterologous gene expression. Gene expression systems using nature for the art of expression 1999, Academic Press, p. 289-329, [chapter 11].
52. Schneider I. Cell lines derived from late embryonic stages of Drosophila melanogaster. J. Embryol. Exp. Morphol. 1972, 27:353-365.
53. Li B., Tsing S., Kosaka A.H., Nguyen B., Osen E.G., Bach C., et al. Expression of human dopamine β-hydroxylase in Drosophila Schneider 2 cells. Biochem J 1996, 313:57-64.
54. Incardona J.P., Rosenberry T.L. Replacement of the glycoinositol phospholipid anchor of Drosophila acetylcholinesterase with a transmembrane domain does not alter sorting in neurons and epithelia but results in behavioral defects. Mol Biol Cell 1996, 7:613-630.
55. Putnak J.R., Coller B.-A., Voss D., Vaughn D.W., Clements D., Houng H.S., et al. Recombinant subunit protein and inactivated virus vaccines for dengue type-2 formulated with new adjuvants induce high-titered virus-neutralizing antibodies and confer protection against virus challenge in rhesus macaques. Vaccine 2005, 23:4442-4452.
56. Clements D.E., Coller B.A., Lieberman M.M., Ogata S., Wang G., Harada K.E., et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28:2705-2715.
57. Modis Y., Ogata S., Clements D., Harrison S.C. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004, 427:313-319.
58. Modis Y., Ogata S., Clements D., Harrison S.C. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 2005, 79:1223-1231.
59. Zhang Y., Zhang W., Ogata S., Clements D., Strauss J.H., Baker T.S., et al. Conformational changes of the flavivirus E glycoprotein. Structure 2004, 12:1607-1618.
60. Rey F.A., Heinz F.X., Mandl C., Kunz C., Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995, 375:291-298.
61. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5:505-517.
62. McKeage K., Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 2011, 71:465-488.
63. McKenzie A., Watt M., Gittleson C. ISCOMATRIX™ vaccines: safety in human clinical studies. Hum Vaccin 2010, 6:237-246.
64. Garçon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Rev Vaccines 2011, 10:471-486.
65. Libraty D.H., Endy T.P., Houng H.S., Green S., Kalayanarooj S., Suntayakorn S., et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002, 185:1213-1221.
66. Drane D., Gittleson C., Boyle J., Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007, 6:761-772.